- Home
- DSY vs EPIX Comparison
DSY vs EPIX Comparison
Compare DSY & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- EPIX
- Stock Information
- Founded
- DSY 2020
- EPIX 2009
- Country
- DSY China
- EPIX Canada
- Employees
- DSY N/A
- EPIX N/A
- Industry
- DSY
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- EPIX Health Care
- Exchange
- DSY Nasdaq
- EPIX Nasdaq
- Market Cap
- DSY 77.6M
- EPIX 75.9M
- IPO Year
- DSY N/A
- EPIX N/A
- Fundamental
- Price
- DSY $1.29
- EPIX $1.72
- Analyst Decision
- DSY
- EPIX Hold
- Analyst Count
- DSY 0
- EPIX 3
- Target Price
- DSY N/A
- EPIX $2.00
- AVG Volume (30 Days)
- DSY 11.3K
- EPIX 68.7K
- Earning Date
- DSY 02-10-2025
- EPIX 08-04-2025
- Dividend Yield
- DSY N/A
- EPIX N/A
- EPS Growth
- DSY 120.37
- EPIX N/A
- EPS
- DSY 0.01
- EPIX N/A
- Revenue
- DSY $7,323,356.00
- EPIX N/A
- Revenue This Year
- DSY N/A
- EPIX N/A
- Revenue Next Year
- DSY N/A
- EPIX N/A
- P/E Ratio
- DSY $102.83
- EPIX N/A
- Revenue Growth
- DSY 16.37
- EPIX N/A
- 52 Week Low
- DSY $0.75
- EPIX $1.40
- 52 Week High
- DSY $6.98
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- DSY 42.27
- EPIX 55.34
- Support Level
- DSY $1.27
- EPIX $1.60
- Resistance Level
- DSY $1.39
- EPIX $1.73
- Average True Range (ATR)
- DSY 0.07
- EPIX 0.04
- MACD
- DSY -0.00
- EPIX 0.00
- Stochastic Oscillator
- DSY 45.28
- EPIX 76.50
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.